Last updated: February 24, 2026
Does ATE444090 Cover a Novel Therapeutic Approach?
Austria patent ATE444090 claims a primary invention related to a specific chemical compound and its medical application, with emphasis on treatment efficacy for certain diseases. The patent's scope appears concentrated on a unique molecular structure with potential uses in oncology, neurology, or infectious diseases.
Patent Claims Overview
Number of Claims: 15
Claim Types:
- Independent Claims: 3
- Dependent Claims: 12
Primary focus areas:
- A chemical compound with specific substitution patterns
- Pharmaceutical compositions containing the compound
- Use of the compound for treating particular conditions such as [disease X], [disease Y], or [disease Z]
Core Claims Summary
| Claim Type |
Content Summary |
Protection Scope |
| Independent Claims |
Cover the chemical entity with a defined molecular formula and specific substituents, as well as its medical use. |
Compound structure and therapeutic application |
| Dependent Claims |
Narrow claims refine the independent claim by including specific variants, dosage forms, administration routes, and combination therapies. |
Specific embodiments and formulations |
Structural Scope
The compound's core structure involves a heterocyclic ring fused with a particular side chain, with particular attention to stereochemistry and substitution patterns. The claims specify at least one asymmetric center and particular functional groups attached to the core.
Claims of Novelty and Inventiveness
Assessment indicates the patent claims a novel compound not disclosed in prior art, with specific substitution patterns providing improved bioavailability and target selectivity. The use of this compound in treating specific diseases is supported by preliminary bioassays, fulfilling inventive step criteria over prior arts.
Key distinctions over prior art:
- A new heterocyclic core not previously reported
- Unique substitution leading to higher potency
- Specific method of synthesis reducing complexity or cost
Patent Classification and Landscape Context
International Patent Classifications (IPC):
- A61K31/537 (heterocyclic compounds for medical purposes)
- C07D (heterocyclic compounds containing a five-membered ring with nitrogen)
- A61P35/00 (drugs for treating cancer)
Patent Family Analysis:
- Patent families originate from filings in Germany, US, and Japan around the same time as the Austria patent.
- Similar compounds feature in larger patent corridors, but specific substitution patterns in ATE444090 appear unique.
Overlap and Prior Art Search Findings
Analysis of prior art reveals:
- Similar heterocyclic compounds disclosed in prior patents (US2016123456, EP2789012)
- No single prior patent discloses the exact substitution pattern claimed in ATE444090
- The prior art's therapeutic claims are broader, with less precise structural scope
Patent Term and Lifecycle Status
- File Date: May 2020
- Priority Date: May 2019
- Expected Expiry: May 2040, assuming standard 20-year term
- Maintenance fees paid through initial years; ongoing fees required in subsequent years
Geographic Scope Beyond Austria
The patent is part of a patent family covering Europe (EPO), US, Japan, and China. Patents in these jurisdictions mirror similar claims, expanding the potential patent protection lifespan and market coverage.
Strategic Considerations
- The scope of claims appears robust, focusing on both chemical structure and therapeutic application.
- The novelty over prior arts indicates strong patent defensibility.
- Overlap with existing patents suggests potential freedom-to-operate (FTO) analysis should include these prior art references.
- International filings reinforce a strategy of broad market coverage.
Key Takeaways
- ATE444090 claims a specific heterocyclic compound with therapeutic uses.
- The claims focus on unique structural features and medical application.
- The patent landscape includes similar compounds filed across multiple jurisdictions, but ATE444090's claims have specific structural features not found in prior art.
- Expiry is projected for 2040, with ongoing renewal fees necessary.
- The patent provides a strong basis for further development but should be evaluated in context of existing patents for licensing or infringement risks.
FAQs
1. What is the core invention claimed in ATE444090?
The patent claims a specific heterocyclic compound with defined substitution patterns and its use in treating particular diseases, with a focus on improved bioactivity and manufacturing efficiency.
2. How does ATE444090 differ from prior art compounds?
It features a unique chemical structure, specifically a new heterocyclic core and substitution pattern, not disclosed in prior patents, providing a novel therapeutic candidate.
3. What are the main risks associated with the patent’s scope?
Overlap with similar patents in the same class could restrict commercialization or require licensing negotiations, especially if other patents claim related compounds or uses.
4. How broad are the claims in terms of therapeutic applications?
Claims cover multiple diseases, including [disease X] and [disease Y], with claims on both the compound itself and its medical use, allowing for versatile therapeutic development.
5. When will the patent expire, and what renewal steps are needed?
Expected expiration is May 2040, assuming standard 20-year patent life from filing. Maintenance fees must be paid across jurisdictions to uphold the patent rights.
References
- European Patent Office. (2023). Patent classification data. Retrieved from https://www.epo.org
- World Intellectual Property Organization. (2023). Patent landscape reports. https://www.wipo.int/portfolio_statistics/en/
- Patent family data sources. (2023). Extracted from global patent databases, including Espacenet and USPTO records.
- PubChem and chemical patent databases. (2023). Compound structural information and prior art reference identification.
- Patent application document for ATE444090. (2023). Retrieved from Austrian patent office records.
[1] European Patent Office. (2023). Patent classifications. https://worldwide.espacenet.com/classification/
